Boehringer Ingelheim has licenced a preclinical fusion protein from Korean Yuhan Corp. that activates both GLP-1R and FGF21R to treat Nonalcoholic Steatohepatitis (NASH). Boehringer Ingelheim will pay $40m upfront and in near-term payments to acquire the commercialisation rights to the compound. Under the agreement, Yuhan Corp. is eligible to receive up to USD 830 million in potential milestone payments plus tiered royalties on future net sales.
Gilead Sciences Inc said on Tuesday it will partner with privately held insitro to develop therapies for a fatty liver disease called non-alcoholic steatohepatitis (NASH), as the drugmaker tries to overcome its recent setback in developing NASH treatments.
Gilead Sciences has announced its intent to initiate a clinical collaboration with Novo Nordisk for a trial combining compounds from their respective pipelines in nonalcoholic steatohepatitis (NASH).
COPENHAGEN (Reuters) - Novo Nordisk and Gilead Sciences will join forces on a clinical trial combining drugs from the two pharmaceutical firms to treat a progressive fatty liver disease known as NASH.
As the International Liver Congress kicks off in Vienna, Big Biotech Gilead Sciences is one of the first players to reveal its NASH data.